Ripple - Our Science


Let’s be honest: the cannabis industry is rife with fraud. Consumers can’t tell at a glance whether a product contains the THC it says it does, has dangerous levels of salmonella, or pulled its benefit claims out of thin air. Test results are often faked, corners are often cut, and everyone knows that the powers that be won’t do anything about it. When proof is costly and lying is free, we shouldn’t be surprised when charlatanism thrives.

They say science doesn’t sell. Maybe so, but it still matters. We wouldn’t call our products ‘fast-acting’ if we didn’t have the research to back it up. And not just any research — credible research. That means: human subjects, real-world products, academic clinicians, and results published in peer-reviewed journals.

Why invest in research?

Consumer safety is of utmost importance to us, and we will only make claims that we can support. Research is fundamental to our product innovation and to our brand. We want to propel the THC industry forward and give it the credence it deserves. Those who are making unfounded claims and faking research do a disservice to us all.

Our clinical research program

Our research program began with an anecdote, “I feel high quicker with your products than with other products.” We felt the same way, but we also recognize that the placebo effect is real, and self-reports about something as subjective as “feeling high” are inherently unreliable. Fortunately, THC can be measured in the blood, and blood measurements aren’t affected by the placebo effect.

Winter 2018 | THC PK I

Following a number of anecdotal consumer reports claiming that RIPPLE-infused edibles offered faster subjective effect onset versus competing cannabis edibles, Stillwater Foods (Ripple) undertook an effort to quantitate the absorption profile of RIPPLE into the bloodstream.


  • 5 healthy male & female subjects, ages 27-50
  • 10mg dose of Ripple in 240ml of room temperature (22° C) water
  • All subjects fasted for 12 hours
  • Each subject drank the entire 240 ml of water within 30-60 seconds 
  • Blood samples were taken at 0 (baseline), 15, 30, 60, 90 and 120 minutes following ingestion


  • All test subjects experienced rapid absorption of THC within 15 minutes of consumption.
  • Peak change in carboxy-THC levels was identified in all subjects at 60 minutes.
  • The levels of carboxy-THC steadily decreased from 60 minutes through the final blood draw at 120 minutes.
Download the overview

Summer 2019 – Winter 2020 | CBD PK 2


Our sister company, Caliper Foods, sought to substantiate our product claims. Pharmacokinetic data (including rate and speed of absorption) are a critical foundation for claims such as “fast acting,” or “superior bioavailability.” This was the first human clinical substantiation of such claims—andthe first to do so using commercially available CBD products.


Colorado State University researchers compared pharmacokinetics of Caliper’s suite of soluble cannabinoid products with two controls: oil-based CBD tincture and unemulsified CBD isolate—the forms most widely available to today’s consumers.

  • Colorado State University IRB-approved
  • Double-blind, randomized crossover design
  • 15 healthy male & female subjects, ages 21-62
  • 30mg dose of each product given on five different days
  • All subjects had faster for 6 hours
  • Blood samples were taken at 0, 10, 20, 30, 45, 60, 120, 180, & 240 minutes following ingestion
  • CBD blood levels were determined using UHPLC mass spectrometry


  • Absorption began within 10 minutes—significantly faster than either control, which did not reach appreciable blood levels until 60 minutes.
  • How formulations delivered CBD into the bloodstream at 30 minutes:
    • Caliper 5% CBD Liquid Concentrate (gum arabic-based): 424x faster than isolate & 64x faster than tincture
    • Caliper 20% CBD Liquid Concentrate (quillaia-based): 218x faster than isolate & 33x faster than tincture
    • Caliper 5% CBD Powder: 142x faster than isolate & 22x faster than tincture
Download the overview

Summer 2021 | THC PK 3


The purpose of the study was to describe and compare the pharmacokinetics of five commercial edible marijuana products, determine the influence of body composition on pharmacokinetics, and, in light of epidemiology suggesting marijuana may offer diabetes protection, explore the influence of edible marijuana on glucose tolerance.


  • Designed and led by the Director of Colorado State University’s Integrative Biology Lab, Dr. Christopher Bell.
  • Randomized, placebo-controlled crossover design
  • 7 healthy, regular cannabis users
  • Each subject consumed 10 mg of THC in 5 different formats (plus placebo) over 6 weeks


  • Ripple products entered the bloodstream within 10 minutes, up to 2.2x faster than the leading gummy brand
  • With Ripple products, you absorb more of the THC you pay for. That makes them a better value, overall.
download the overview